THCh is a naturally occurring minor cannabinoid first isolated from cannabis in 2020, with meaningfully stronger CB1 receptor binding than standard Delta-9 THC.

H4CBD is a hydrogenated form of CBD that binds more strongly to CB1 receptors, producing mild psychoactive effects that traditional CBD does not. For brands and formulators, the choice between them comes down to effect profile, compliance risk, and product strategy.

CBN does not occur in meaningful amounts in hemp; it forms through oxidative degradation of Δ9-THC, first converting to cannabinolic acid (CBNa) and then to CBN via decarboxylation.